Investor directory

Histogen

Histogen Inc. is a clinical-stage regenerative medicine company based in San Diego, California, specializing in innovative therapies derived from products of cells cultured under simulated embryonic conditions. Founded in 2007 by Dr. Gail Naughton, the company focuses on developing proprietary hypoxia-generated growth factor technology and stem cell-free biologic products aimed at stimulating the body's natural repair mechanisms. Histogen's key offerings include human multipotent cell conditioned media, human extracellular matrix, and hair stimulating complex. The company is advancing several therapeutic candidates, including HST-003 for joint cartilage repair and HST-004 for spinal disc repair. With a commitment to addressing significant unmet medical needs, Histogen targets multi-billion dollar global markets by harnessing its unique biological platform for tissue regeneration and repair.

Top Stages

Acquisition
http://www.histogen.com
https://crunchbase.com/organization/histogen
https://linkedin.com/company/histogen
https://pitchbook.com/profiles/company/51339-79
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=44460054

Mark Hubka

Executive Director of Medical Affairs

1 past transactions

Conatus Pharmaceuticals

Acquisition in 2020
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in the development of innovative therapeutics for the treatment of liver diseases. Founded in 2005 and headquartered in San Diego, California, the company is primarily focused on advancing treatments for conditions such as hepatitis C virus infection, portal hypertension, and liver fibrosis associated with nonalcoholic steatohepatitis. Its lead product candidate, Emricasan, is an orally active caspase protease inhibitor currently undergoing Phase IIb clinical trials. Additionally, Conatus is developing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage aimed at addressing chronic diseases linked to inflammasome pathways. The company also has a collaboration agreement with Novartis to conduct multiple Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.